Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Consumer Services, Technology and Basic Materials sectors led shares lower. At the close in...
Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Oil & Gas, Industrials and Financials sectors led shares higher while losses in the Healthcare,...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Technology, Industrials and Healthcare sectors led shares higher. At the close in NYSE, the...
Bausch Health Companies Inc. (NYSE:BHC) announced that it has entered into a definitive agreement to acquire certain assets of biopharmaceutical Synergy Pharmaceuticals Inc....
Allergan plc (NYSE:AGN) issued a statement in response to a letter from public shareholders from Appaloosa and Senator Investment Group of the company expressing disappointment...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Buy||Strong Sell||Strong Sell||Strong Sell|
|Technical Indicators||Sell||Strong Sell||Strong Sell||Sell||Strong Sell|
|Summary||Strong Sell||Neutral||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Belt Hold Bearish||15||Current|
|Evening Doji Star||15||Current|
|Doji Star Bearish||15||2||Mar 18, 2019 03:15PM|
|Stick Sandwich||30||3||Mar 18, 2019 02:00PM|
|Bullish Engulfing||15||3||Mar 18, 2019 03:00PM|
|Petroleo Brasileiro Petrobras ADR||17.11||17.11||16.60||+0.52||+3.13%||22.90M||18/03|
|X Financial A||6.1800||6.3500||5.4500||+0.7300||+13.39%||42.86K||18/03|
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.Read More
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.